Prospects for Venetoclax in Myelodysplastic Syndromes

This article reviews the biology of BCL-2, focusing on its relationship to the myeloid microenvironment, and discusses the rationale for BCL-2 inhibition in myelodysplastic syndrome (MDS). Clinical trials testing venetoclax in MDS patients are under way. Potential biomarkers for clinical response to BCL-2 inhibition are discussed. Therapeutic opportunities for venetoclax in the therapeutic landscape of MDS are explored.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Source Type: research